RxDoctor Payments Data

James Martin, MD

Family Medicine · Elgin, SCNPI 1588622641

Payments from drug & device makers

$11,682in general payments, 2019–2025

Across 703 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$1K
  • Amgen$883
  • Novo Nordisk$746
  • Takeda Pharmaceuticals U.S.A., Inc.$630
  • Amarin Pharma, Inc.$500
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$11,51299%
  • Education$1701%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca59$1,435
AbbVie(2 entities)127$1,113
Amgen(2 entities)67$883
Novo Nordisk41$746
Takeda Pharmaceuticals U.S.A., Inc.28$630
Amarin Pharma, Inc.31$500
Antares Pharma, Inc.22$362
Boehringer Ingelheim16$347
Lilly USA, LLC23$346
Pfizer21$341
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)16$306
Esperion Therapeutics, Inc.16$280
Corcept Therapeutics11$265
Eisai Inc.14$227
Bayer8$217
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$211
Astellas Pharma US Inc11$199
Johnson & Johnson10$192
Kowa Pharmaceuticals America, Inc.11$149
Exact Sciences8$148
Renalytix AI, Inc.8$147
Azurity Pharmaceuticals, Inc.9$142
GSK8$140
Paratek Pharmaceuticals, Inc.7$135
Biohaven Pharmaceuticals, Inc.7$134
Biohaven Pharmaceutical Holding Company Ltd.7$127
Tolmar, Inc.8$124
Novartis7$117
Phathom Pharmaceuticals, Inc.7$117
Genentech USA, Inc.6$112
Teva Pharmaceuticals USA, Inc.2$97
Sumitomo Pharma America, Inc.3$87
Lundbeck LLC3$84
Merck6$83
Axsome Therapeutics, Inc.4$72
Jazz Pharmaceuticals Inc.3$66
Idorsia Pharmaceuticals US Inc4$64
Ironwood Pharmaceuticals, Inc4$60
Halozyme Inc4$59
Sunovion Pharmaceuticals Inc.4$57
Otsuka America Pharmaceutical, Inc.2$45
Acerus Pharmaceuticals Corporation3$44
Abbott2$41
Endo Pharmaceuticals Inc.2$39
Medicure Pharma Inc.1$38
Bausch Health US, LLC2$36
Inari Medical, Inc.1$36
Zyla Life Sciences, Inc.2$35
Clarus Therapeutics Inc.3$34
Nabriva Therapeutics, PLC2$34
Insulet Corporation2$33
Vanda Pharmaceuticals Inc.1$32
Edwards Lifesciences1$31
Regeneron Healthcare Solutions, Inc.1$31
Currax Pharmaceuticals LLC2$26
Medtronic1$25
Duchesnay USA Incorporated1$21
Verity Pharmaceuticals Inc.1$21
Boston Scientific1$19
Ultragenyx Pharmaceutical Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,682 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$340,261
Medicare patients
374
Services billed
9,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide175$187,415
EliquisApixaban214$160,749
OxycontinOxycodone Hcl30$97,870
XareltoRivaroxaban88$79,087
JardianceEmpagliflozin59$69,616
OtezlaApremilast13$63,939
OzempicSemaglutide41$52,941
Repatha SureclickEvolocumab82$51,534
FarxigaDapagliflozin Propanediol46$40,276
VraylarCariprazine Hcl25$34,457
GemtesaVibegron44$27,215
MyrbetriqMirabegron27$22,367
RybelsusSemaglutide12$21,441
ViberziEluxadoline14$21,218
Budesonide ErBudesonide20$19,986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$346$187,415175 claims
PfizerEliquis, Lyrica$341$170,293225 claims
Johnson & JohnsonXarelto$192$79,08788 claims
Boehringer IngelheimJardiance, Glyxambi$347$77,42972 claims
Novo NordiskOzempic, Rybelsus$746$74,38253 claims
AbbVieVraylar, Viberzi, Linzess, Armour Thyroid$1,113$72,761167 claims
AmgenOtezla$883$63,93913 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,435$47,01157 claims
Sumitomo Pharma America, Inc.Gemtesa$87$27,21544 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$630$23,02343 claims
Astellas Pharma US IncMyrbetriq$199$22,36727 claims
Otsuka America Pharmaceutical, Inc.Rexulti$45$17,69912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Elgin

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →